← Back to Screener
Spero Therapeutics, Inc. Common Stock (SPRO)
Price$2.68
Favorite Metrics
Price vs S&P 500 (26W)11.80%
Price vs S&P 500 (4W)1.49%
Market Capitalization$152.83M
P/E Ratio (Annual)17.83x
All Metrics
Book Value / Share (Quarterly)$1.05
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.68%
Cash Flow / Share (Quarterly)$-0.22
Price vs S&P 500 (YTD)10.66%
Net Profit Margin (TTM)12.83%
EPS (TTM)$0.05
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$0.05
Revenue Growth (5Y)48.25%
EPS (Annual)$0.15
ROI (Annual)14.52%
Net Profit Margin (5Y Avg)-137.28%
Cash / Share (Quarterly)$0.71
P/E Basic Excl Extra (TTM)17.83x
Revenue Growth QoQ (YoY)174.51%
P/E Normalized (Annual)17.83x
ROA (Last FY)12.44%
Revenue Growth TTM (YoY)39.24%
EBITD / Share (TTM)$0.11
ROE (5Y Avg)-55.12%
Operating Margin (TTM)9.45%
Cash Flow / Share (Annual)$-0.22
P/B Ratio2.59x
P/B Ratio (Quarterly)2.22x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.69x
Net Interest Coverage (TTM)-79.03x
ROA (TTM)13.04%
EV / EBITDA (TTM)17.81x
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)7.59x
Quick Ratio (Quarterly)7.40x
3-Month Avg Trading Volume0.33M
52-Week Price Return276.60%
P/E Incl Extra (TTM)17.83x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$1.01
P/S Ratio (Annual)2.29x
Asset Turnover (Annual)0.97x
52-Week High$3.22
Operating Margin (5Y Avg)-138.01%
EPS Excl Extra (Annual)$0.15
Tangible BV CAGR (5Y)-2.14%
26-Week Price Return15.79%
Quick Ratio (Annual)7.40x
13-Week Price Return5.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.59x
Enterprise Value$112.569
Revenue / Share Growth (5Y)22.11%
Asset Turnover (TTM)1.02x
Book Value / Share Growth (5Y)-25.34%
Revenue / Employee (Annual)$2
Pretax Margin (Annual)13.22%
Cash / Share (Annual)$0.71
3-Month Return Std Dev47.22%
Net Income / Employee (TTM)$0
ROE (Last FY)14.52%
Net Interest Coverage (Annual)-52.52x
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)8.77x
Receivables Turnover (TTM)7.37x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.05
Receivables Turnover (Annual)28.73x
ROI (TTM)22.53%
P/S Ratio (TTM)2.29x
Pretax Margin (5Y Avg)-136.71%
Revenue / Share (Annual)$1.13
Tangible BV / Share (Annual)$1.45
Forward P/E4.00x
Price vs S&P 500 (52W)246.77%
P/E Ratio (TTM)17.83x
Year-to-Date Return13.30%
5-Day Price Return-5.04%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)-25.35%
Net Profit Margin (Annual)12.83%
Month-to-Date Return12.82%
Cash Flow / Share (TTM)$-0.02
EBITD / Share (Annual)$0.11
Operating Margin (Annual)9.45%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-47.92%
P/E Excl Extra (TTM)17.83x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.05
P/TBV (Quarterly)1.17x
P/B Ratio (Annual)2.22x
Pretax Margin (TTM)13.22%
Book Value / Share (Annual)$1.05
Price vs S&P 500 (13W)4.49%
Beta1.51x
Revenue / Share (TTM)$0.97
ROE (TTM)22.53%
52-Week Low$0.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SPROSpero Therapeutics, Inc. Common Stock | 2.29x | 39.24% | — | — | $2.68 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics for multi-drug-resistant bacterial infections and rare diseases. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic for MDR Gram-negative infections; SPR720 for non-tuberculous mycobacterial infections; and SPR206, an intravenous polymyxin candidate for hospital-acquired MDR Gram-negative infections.